could be they're only putting in a low ball offer hoping GALT management is tired of being kicked down. Eventually there will be too much good news out there to ignore.
Like it says connect the dots. No good reason not to control the company that makes your drug twice as good. You know this was the sameposition they were in with AVASTIN. Anyone remember that DAVANAT make AVASTIN twice as good because it targeted the drug to the cancer cells which are overexpress with GAL-3.
News 
Market Data 
Discover 
